Cargando…
Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies. The metabolomic approaches are developed to discover the novel biomarkers of PDAC. Methods: 550 preoperative, postoperative PDAC and normal controls (NCs) serums were employed to characterize metabo...
Autores principales: | Zhang, Xiaohan, Shi, Xiuyun, Lu, Xin, Li, Yiqun, Zhan, Chao, Akhtar, Muhammad Luqman, Yang, Lijun, Bai, Yunfan, Zhao, Jianxiang, Wang, Yu, Yao, Yuanfei, Li, Yu, Nie, Huan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330680/ https://www.ncbi.nlm.nih.gov/pubmed/32626510 http://dx.doi.org/10.7150/jca.41250 |
Ejemplares similares
-
SCIA: A Novel Gene Set Analysis Applicable to Data With Different Characteristics
por: Li, Yiqun, et al.
Publicado: (2019) -
Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma
por: Guo, Xiaodong, et al.
Publicado: (2022) -
Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023) -
A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma
por: Li, Tiandong, et al.
Publicado: (2023) -
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021)